The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
AP-1 Transcription Factors as Regulators of Immune Responses in Cancer
Open accessAbstract
Immune check point blockade therapy has revolutionized the standard of cancer treatment and is credited with producing remarkable tumor remissions and increase in overall survival. This unprecedented clinical success however is feasible for a limited number of cancer patients due to resistance occurring before or during a course of immunotherapy, which is often associated with activation of oncogenic signaling pathways, co-inhibitory checkpoints upregulation or expansion of immunosuppressive regulatory T-cells (Tregs) in the tumor microenviroment (TME). Targeted therapy aiming to inactivate a signaling pathway such as the Mitogen Activated Protein Kinases (MAPKs) has recently received a lot of attention due to emerging data from preclinical studies indicating synergy with immune checkpoint blockade therapy. The dimeric transcription factor complex Activator Protein-1 (AP-1) is a group of proteins involved in a wide array of cell processes and a critical regulator of nuclear gene expression during T-cell activation. It is also one of the downstream targets of the MAPK signaling cascade. In this review, we will attempt to unravel the roles of AP-1 in the regulation of anti-tumor immune responses, with a focus on the regulation of immune checkpoints and Tregs, seeking to extract useful insights for more efficacious immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Park, J.-H., Adoro, S., Guinter, T., Erman, B., Alag, A. S., Catalfamo, M., Kimura, M. Y., Cui, Y., Lucas, P. J., Gress, R. E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1840 · Cited by 5,835
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608 · cited 1×
“Regulatory cells (Tregs) is a population of CD4+ T cells that are characterized by the expression of CD25 and the forkhead transcription factor FOXP3 [104,105].”
BackgroundPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Regulatory T Cells and Immune Tolerance
Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,325
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
AP-1 as a regulator of cell life and death
Shaulian, E., & Karin, M. (2002) · Nature Cell Biology · doi:10.1038/ncb0502-e131 · Cited by 2,961 · cited 3×
“Adjacent to the leucine zipper lies a basic DNA binding domain which is rich in basic amino acids and is responsible for DNA-binding in either 12-O-tetradecanoylphorbol-13-acetate (TPA) response elements (5′-TGAG/CTCA-3′) or cAMP response elements (CRE, 5′-TGACGTCA-3′) [21,28].”
BackgroundCTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
Angel, P., Imagawa, M., Chiu, R., Stein, B., Imbra, R. J., Rahmsdorf, H. J., Jonat, C., Herrlich, P., & Karin, M. (1987) · Cell · doi:10.1016/0092-8674(87)90611-8 · Cited by 2,931
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766 · cited 1×
“The central role of CTLA4 for keeping T cell activation in check was highlighted from studies with genetically modified mice that are deficient for CTLA-4, which are characterized by profound immune dysregulation and autoimmune disease [96].”
BackgroundThe Regulation of AP-1 Activity by Mitogen-activated Protein Kinases
Karin, M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.28.16483 · Cited by 2,431
AP-1: a double-edged sword in tumorigenesis
Eferl, R., & Wagner, E. F. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1209 · Cited by 2,242
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Smith-Garvin, J. E., Koretzky, G. A., & Jordan, M. S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132706 · Cited by 2,144
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,079
Hibi, M., Lin, A., Smeal, T., Minden, A., & Karin, M. (1993) · Genes & Development · doi:10.1101/gad.7.11.2135 · Cited by 1,886 · cited 1×
“An additional mechanism contributing to AP-1 activation from TCR engagement stems again from the MAPKs and the activation of the Jun-N-terminal kinase (JNKs) [40] (Figure 1).”
BackgroundRegulatory T cells in cancer immunotherapy
Tanaka, A., & Sakaguchi, S. (2017) · Cell Research · doi:10.1038/cr.2016.151 · Cited by 1,860
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689 · cited 1×
“In the direct pathway, binding of PD-1 to its ligand, the B7 member PD-L1, strongly interferes with TCR/CD28 signal transduction and terminates ZAP70 and PI3K phosphorylation by recruiting the SHP1 and SHP2 phosphatases to its tyrosine phosphorylated ITIM and ITSM motifs [82,83].”
BackgroundMolecular mechanism and function of CD40/CD40L engagement in the immune system
Elgueta, R., Benson, M. J., De Vries, V. C., Wasiuk, A., Guo, Y., & Noelle, R. J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00782.x · Cited by 1,625
NFAT proteins: key regulators of T-cell development and function
Macian, F. (2005) · Nature Reviews Immunology · doi:10.1038/nri1632 · Cited by 1,569
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
Schwartz, R. H. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141110 · Cited by 1,487
ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28
Hutloff, A., Dittrich, A. M., Beier, K. C., Eljaschewitsch, B., Kraft, R., Anagnostopoulos, I., & Kroczek, R. A. (1999) · Nature · doi:10.1038/16717 · Cited by 1,482
Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415
Mechanisms of resistance to immune checkpoint inhibitors
Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.434 · Cited by 1,383 · cited 1×
“Data from several clinical trials suggest that patients are stratified in the following three groups according to their resistance to ICB therapy: (1) responders, patients who respond to initial treatment and continue to respond, (2) non-responders, those that do not succeed in responding to ICB (primary resistance),…”
MethodInfluentialMolecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.11.006 · Cited by 1,354
Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade
Pauken, K. E., Sammons, M. A., Odorizzi, P. M., Manne, S., Godec, J., Khan, O., Drake, A. M., Chen, Z., Sen, D. R., Kurachi, M., et al. (2016) · Science · doi:10.1126/science.aaf2807 · Cited by 1,348
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2007) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,344
The Role of the CD28 Receptor During T Cell Responses to Antigen
Linsley, P. S., & Ledbetter, J. A. (1993) · Annual Review of Immunology · doi:10.1146/annurev.iy.11.040193.001203 · Cited by 1,298
The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain
Marais, R., Wynne, J., & Treisman, R. (1993) · Cell · doi:10.1016/0092-8674(93)90237-k · Cited by 1,275
Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
Chen, L. (2004) · Nature Reviews Immunology · doi:10.1038/nri1349 · Cited by 1,257
Differential T Cell Costimulatory Requirements in CD28-Deficient Mice
Shahinian, A., Pfeffer, K., Lee, K. P., Kündig, T. M., Kishihara, K., Wakeham, A., Kawai, K., Ohashi, P. S., Thompson, C. B., & Mak, T. W. (1993) · Science · doi:10.1126/science.7688139 · Cited by 1,257
Fantini, M. C., Becker, C., Monteleone, G., Pallone, F., Galle, P. R., & Neurath, M. F. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.9.5149 · Cited by 1,135
Hori, S., Nomura, T., & Sakaguchi, S. (2017) · The Journal of Immunology · doi:10.1093/jimmunol/198.3.981 · Cited by 1,066
Pitt, J. M., Vétizou, M., Daillère, R., Roberti, M. P., Yamazaki, T., Routy, B., Lepage, P., Boneca, I. G., Chamaillard, M., Kroemer, G., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.001 · Cited by 1,041
c-Jun dimerizes with itself and with c-Fos, forming complexes of different DNA binding affinities
Halazonetis, T. D., Georgopoulos, K., Greenberg, M. E., & Leder, P. (1988) · Cell · doi:10.1016/0092-8674(88)90147-x · Cited by 1,035
Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967
Frederick, D. T., Piris, A., Cogdill, A. P., Cooper, Z. A., Lezcano, C., Ferrone, C. R., Mitra, D., Boni, A., Newton, L. P., Liu, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1630 · Cited by 944
JNK is involved in signal integration during costimulation of T lymphocytes
Su, B., Jacinto, E., Hibi, M., Kallunki, T., Karin, M., & Ben-Neriah, Y. (1994) · Cell · doi:10.1016/0092-8674(94)90056-6 · Cited by 906
CD28 and CTLA-4 coreceptor expression and signal transduction
Rudd, C. E., Taylor, A., & Schneider, H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00770.x · Cited by 898
The Transcription Factor NFAT Promotes Exhaustion of Activated CD8 + T Cells
Martinez, G. J., Pereira, R. M., Äijö, T., Kim, E. Y., Marangoni, F., Pipkin, M. E., Togher, S., Heissmeyer, V., Zhang, Y. C., Crotty, S., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.01.006 · Cited by 857
Sheppard, K.-A., Fitz, L. J., Lee, J. M., Benander, C., George, J. A., Wooters, J., Qiu, Y., Jussif, J. M., Carter, L. L., Wood, C. R., et al. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.07.083 · Cited by 791
Partners in transcription: NFAT and AP-1
Macián, F., López-Rodríguez, C., & Rao, A. (2001) · Oncogene · doi:10.1038/sj.onc.1204386 · Cited by 766
Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C.-N. J., Sloss, C. M., Ferrone, C. R., Flaherty, K. T., Lawrence, D. P., Fisher, D. E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0118 · Cited by 742
Lee, W., Haslinger, A., Karin, M., & Tjian, R. (1987) · Nature · doi:10.1038/325368a0 · Cited by 731
Ebert, P. J. R., Cheung, J., Yang, Y., McNamara, E., Hong, R., Moskalenko, M., Gould, S. E., Maecker, H., Irving, B. A., Kim, J. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.024 · Cited by 713
Jun-B differs in its biological properties from, and is a negative regulator of, c-Jun
Chiu, R., Angel, P., & Karin, M. (1989) · Cell · doi:10.1016/0092-8674(89)90754-x · Cited by 688
Transcriptional Mechanisms Underlying Lymphocyte Tolerance
Macián, F., Garcı́a-Cózar, F., Im, S.-H., Horton, H. F., Byrne, M. C., & Rao, A. (2002) · Cell · doi:10.1016/s0092-8674(02)00767-5 · Cited by 687
Green, M. R., Rodig, S., Juszczynski, P., Ouyang, J., Sinha, P., O'Donnell, E., Neuberg, D., & Shipp, M. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1942 · Cited by 685
The Interaction Properties of Costimulatory Molecules Revisited
Collins, A. V., Brodie, D. W., Gilbert, R. J. C., Iaboni, A., Manso-Sancho, R., Walse, B., Stuart, D. I., van der Merwe, P. A., & Davis, S. J. (2002) · Immunity · doi:10.1016/s1074-7613(02)00362-x · Cited by 684
Control of Immunity by the TNFR-Related Molecule OX40 (CD134)
Croft, M. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101243 · Cited by 548
Fos/AP‐1 proteins in bone and the immune system
Wagner, E. F., & Eferl, R. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00332.x · Cited by 537
Zerial, M., Toschi, L., Ryseck, R. P., Schuermann, M., Müller, R., & Bravo, R. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb03441.x · Cited by 531
The CD28-Related Molecule ICOS Is Required for Effective T Cell–Dependent Immune Responses
Coyle, A. J., Lehar, S., Lloyd, C., Tian, J., Delaney, T., Manning, S., Nguyen, T., Burwell, T., Schneider, H., Gonzalo, J. A., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00011-x · Cited by 520
Quigley, M., Pereyra, F., Nilsson, B., Porichis, F., Fonseca, C., Eichbaum, Q., Julg, B., Jesneck, J. L., Brosnahan, K., Imam, S., et al. (2010) · Nature Medicine · doi:10.1038/nm.2232 · Cited by 517
Jiang, X., Zhou, J., Giobbie-Hurder, A., Wargo, J., & Hodi, F. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2731 · Cited by 485
jun-B inhibits and c-fos stimulates the transforming and trans-activating activities of c-jun
Schütte, J., Viallet, J., Nau, M., Segal, S., Fedorko, J., & Minna, J. (1989) · Cell · doi:10.1016/0092-8674(89)90755-1 · Cited by 482
Functions of CD40 on B cells, dendritic cells and other cells
Kooten, C. V., & Banchereau, J. (1997) · Current Opinion in Immunology · doi:10.1016/s0952-7915(97)80078-7 · Cited by 472
Acquired resistance to immunotherapy and future challenges
Restifo, N. P., Smyth, M. J., & Snyder, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.2 · Cited by 467
Blocked Signal Transduction to the ERK and JNK Protein Kinases in Anergic CD4 + T Cells
Li, W., Whaley, C. D., Mondino, A., & Mueller, D. L. (1996) · Science · doi:10.1126/science.271.5253.1272 · Cited by 427
Molecular Mechanisms Underlying FOXP3 Induction in Human T Cells
Mantel, P.-Y., Ouaked, N., Rückert, B., Karagiannidis, C., Welz, R., Blaser, K., & Schmidt-Weber, C. B. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.6.3593 · Cited by 399
Fang, W., Zhang, J., Hong, S., Zhan, J., Chen, N., Qin, T., Tang, Y., Zhang, Y., Kang, S., Zhou, T., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2608 · Cited by 398
Transcriptional regulation in the immune system: all roads lead to AP-1
Foletta, V. C., Segal, D. H., & Cohen, D. R. (1998) · Journal of Leukocyte Biology · doi:10.1002/jlb.63.2.139 · Cited by 390
Liu, C., Peng, W., Xu, C., Lou, Y., Zhang, M., Wargo, J. A., Chen, J. Q., Li, H. S., Watowich, S. S., Yang, Y., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1626 · Cited by 381
Mathas, S., Hinz, M., Anagnostopoulos, I., Krappmann, D., Lietz, A., Jundt, F., Bommert, K., Mechta‐Grigoriou, F., Stein, H., Dörken, B., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf389 · Cited by 375
Blocked Ras Activation in Anergic CD4 + T Cells
Fields, P. E., Gajewski, T. F., & Fitch, F. W. (1996) · Science · doi:10.1126/science.271.5253.1276 · Cited by 370
Regulation of IL-4 expression by the transcription factor JunB during T helper cell differentiation
Li, B. (1999) · The EMBO Journal · doi:10.1093/emboj/18.2.420 · Cited by 365
Zerdes, I., Matikas, A., Bergh, J., Rassidakis, G. Z., & Foukakis, T. (2018) · Oncogene · doi:10.1038/s41388-018-0303-3 · Cited by 292
Self-citationRincón, M., & Flavell, R. A. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06757.x · Cited by 289
PD1 signal transduction pathways in T cells
Arasanz, H., Gato-Cañas, M., Zuazo, M., Ibañez-Vea, M., Breckpot, K., Kochan, G., & Escors, D. (2017) · Oncotarget · doi:10.18632/oncotarget.17232 · Cited by 270
TRAF Proteins in CD40 Signaling
Bishop, G. A., Moore, C. R., Xie, P., Stunz, L. L., & Kraus, Z. J. (2007) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-70630-6_11 · Cited by 194
Xu, L., Kitani, A., Stuelten, C., McGrady, G., Fuss, I., & Strober, W. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.001 · Cited by 188
The T-cell-receptor signaling network
Huse, M. (2009) · Journal of Cell Science · doi:10.1242/jcs.042762 · Cited by 183
Feng, Y., Roy, A., Masson, E., Chen, T.-T., Humphrey, R., & Weber, J. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3243 · Cited by 183
Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells
Brea, E. J., Oh, C. Y., Manchado, E., Budhu, S., Gejman, R. S., Mo, G., Mondello, P., Han, J. E., Jarvis, C. A., Ulmert, D., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0177 · Cited by 173
Revilla, C., Amsen, D., & Kruisbeek, A. M. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.10.1645 · Cited by 166
Hayatsu, N., Miyao, T., Tachibana, M., Murakami, R., Kimura, A., Kato, T., Kawakami, E., Endo, T. A., Setoguchi, R., Watarai, H., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.07.008 · Cited by 166
Sumimoto, H., Takano, A., Teramoto, K., & Daigo, Y. (2016) · PLOS ONE · doi:10.1371/journal.pone.0166626 · Cited by 165
Baccam, M., Woo, S., Vinson, C., & Bishop, G. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.6.3099 · Cited by 158
Gross, J. A., John, T. S., & Allison, J. P. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.8.3201 · Cited by 154
Pelster, M. S., & Amaria, R. N. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919830826 · Cited by 142
Kono, M., Dunn, I. S., Durda, P. J., Butera, D., Rose, L. B., Haggerty, T. J., Benson, E. M., & Kurnick, J. T. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0077 · Cited by 141
The basic region of Fos mediates specific DNA binding.
Nakabeppu, Y., & Nathans, D. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb08561.x · Cited by 137
Zhang, X., Xiao, X., Lan, P., Li, J., Dou, Y., Chen, W., Ishii, N., Chen, S., Xia, B., Chen, K., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.052 · Cited by 134
Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1
Xiao, G., Deng, A., Liu, H., Ge, G., & Liu, X. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206370109 · Cited by 133
JunB regulates homeostasis and suppressive functions of effector regulatory T cells
Koizumi, S.-I., Sasaki, D., Hsieh, T.-H., Taira, N., Arakaki, N., Yamasaki, S., Wang, K., Sarkar, S., Shirahata, H., Miyagi, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07735-4 · Cited by 130
Tsytsykova, A. V., Tsitsikov, E. N., & Geha, R. S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.7.3763 · Cited by 124
Georgopoulos, N. T., Steele, L. P., Thomson, M. J. C. B., Selby, P. J., Southgate, J., & Trejdosiewicz, L. K. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401859 · Cited by 120
CTLA4 ligation attenuates AP-1, NFAT and NF-κB activity in activated T cells
Fraser, J., Rincón, M., McCoy, K. D., & Gros, G. S. L. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199903)29:03<838::aid-immu838>3.0.co;2-p · Cited by 120
Afford, S. C., Ahmed-Choudhury, J., Randhawa, S., Russell, C. L., Youster, J., Crosby, H. A., Eliopoulos, A. G., Hübscher, S. G., Young, L. S., & Adams, D. (2001) · The FASEB Journal · doi:10.1096/fj.01-0088com · Cited by 118
McGuire, K. L., & Iacobelli, M. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.3.1319 · Cited by 102
Lee, S., Gao, B., & Fang, D. (2008) · Blood · doi:10.1182/blood-2007-09-115014 · Cited by 99
The MAPK Pathway Is a Predominant Regulator of HLA-A Expression in Esophageal and Gastric Cancer
Mimura, K., Shiraishi, K., Mueller, A., Izawa, S., Kua, L., So, J., Yong, W., Fujii, H., Seliger, B., Kiessling, R., et al. (2013) · Journal of Immunology · doi:10.4049/jimmunol.1301597 · Cited by 92
Ogawa, C., Tone, Y., Tsuda, M., Peter, C., Waldmann, H., & Tone, M. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301892 · Cited by 92
Granelli‐Piperno, A., & Nolan, P. A. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.8.2734 · Cited by 91
Behrens, A., Sabapathy, K., Graef, I. A., Cleary, M., Crabtree, G. R., & Wagner, E. F. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.4.1769 · Cited by 91
CTLA-4 Ligation Suppresses CD28-induced NF-κB and AP-1 Activity in Mouse T Cell Blasts
Olsson, C., Riebeck, K., Dohlsten, M., & Michaëlsson, E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.20.14400 · Cited by 84
D'Aversa, T. G., Eugenin, E., & Berman, J. W. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21525 · Cited by 72
Targeting the NFAT:AP-1 transcriptional complex on DNA with a small-molecule inhibitor
Mognol, G. P., González‐Avalos, E., Ghosh, S., Spreafico, R., Gudlur, A., Rao, A., Damoiseaux, R. D., & Hogan, P. G. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1820604116 · Cited by 68
TLR7 and CD40 cooperate in IL‐6 production via enhanced JNK and AP‐1 activation
Bush, T. J. V., & Bishop, G. A. (2008) · European Journal of Immunology · doi:10.1002/eji.200737602 · Cited by 65
The transcription factor Batf3 inhibits the differentiation of regulatory T cells in the periphery
Lee, W., Kim, H. S., Hwang, S. S., & Lee, G. R. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.157 · Cited by 62
NF‐κB and AP‐1 regulate activation‐dependent CD137 (4‐1BB) expression in T cells
Kim, J., Kim, H. W., Baek, K., & Kang, C. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00326-0 · Cited by 58
Adenosine promotes Foxp3 expression in Treg cells in sepsis model by activating JNK/AP-1 pathway.
Bao, R., Hou, J., Li, Y., Bian, J., Deng, X., Zhu, X., & Yang, T. (2016) · PubMed · Cited by 54
Post‐transcriptional regulation controlled by E‐cadherin is important for c‐Jun activity in melanoma
Spangler, B., Vardimon, L., Bosserhoff, A., & Kuphal, S. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00787.x · Cited by 35
Dummer, R., Arance, A. M., Hansson, J., Larkin, J., Long, G. V., Gasal, E., Kaper, M., Upalawanna, A., Mookerjee, B., & Atkinson, V. G. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.5_suppl.189 · Cited by 34
Evidence Implicating the Ras Pathway in Multiple CD28 Costimulatory Functions in CD4+ T Cells
Janardhan, S. V., Praveen, K., Marks, R., & Gajewski, T. F. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024931 · Cited by 32
CD28 Signaling Augments Elk-1-Dependent Transcription at the c- fos Gene During Antigen Stimulation
Li, W., Whaley, C. D., Bonnevier, J. L., Mondino, A., Martin, M. E., Aagaard-Tillery, K. M., & Mueller, D. L. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.2.827 · Cited by 29
AP ‐1 is involved in ICOS gene expression downstream of TCR / CD 28 and cytokine receptor signaling
Watanabe, M., Nakajima, S., Ohnuki, K., Ogawa, S., Yamashita, M., Nakayama, T., Murakami, Y., Tanabe, K., & Abe, R. (2012) · European Journal of Immunology · doi:10.1002/eji.201141897 · Cited by 23
Regulation of Mouse 4-1BB Expression: Multiple Promoter Usages and a Splice Variant
Kim, J. D., Kim, C. H., & Kwon, B. S. (2011) · Molecules and Cells · doi:10.1007/s10059-011-0018-6 · Cited by 19
Carrozza, M. L., Jacobs, H., Acton, D., Verma, I. M., & Berns, A. J. M. (1997) · Oncogene · doi:10.1038/sj.onc.1200921 · Cited by 19
Cited by
Immunoinformatics and Vaccine Development: An Overview
Oli, A. N., Obialor, W. O., Ifeanyichukwu, M. O., Odimegwu, D. C., Okoyeh, J. N., Emechebe, G. O., Adejumo, S. A., & Ibeanu, G. C. (2020) · ImmunoTargets and Therapy · doi:10.2147/itt.s241064 · Cited by 281
Song, H., Weinstein, H. N. W., Allegakoen, P., Wadsworth, M. H., Xie, J., Yang, H., Castro, E. A., Lu, K. L., Stohr, B. A., Feng, F. Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27322-4 · Cited by 279
TIRAP in the Mechanism of Inflammation
Rajpoot, S., Wary, K. K., Ibbott, R., Liu, D., Saqib, U., Thurston, T. L. M., & Baig, M. S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.697588 · Cited by 79
Metadata
- Authors
- Atsaves, V., Leventaki, V., Rassidakis, G. Z., & Claret, F. X.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2019-07-23
- Volume
- 11
- Issue
- 7
- Pages
- 1037
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2963295412
- Cited by
- 293
- References
- 119
- FWCI
- 9.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.